| Relapse and/or difficulty reducing GC (n = 14) | Sustained remission without difficulty reducing GC (n = 31) | p valued |
---|---|---|---|
Male/female, n/n | 9/5 | 9/22 | 0.047 |
Age, years | 68 (61–72) | 68 (61–77) | 0.60 |
GPA/MPA, n/n | 3/11 | 11/20 | 0.49 |
MPO-ANCA-positive before treatment | 13 (93%) | 25 (81%) | 0.41 |
PR3-ANCA-positive before treatment | 1 (7%) | 7 (23%) | 0.4 |
BVAS score before treatment | 18 (11–25) | 15 (12–18) | 0.31 |
Glucocorticoids, mg/day | |||
 At 6 months | 15 (11–18) | 13 (10–17) | 0.19 |
 At 12 months | 12 (10–14) | 7 (5–10) | < 0.001 |
 At 18 months | 11 (10–15) | 5 (5–8) | < 0.001 |
Immunosuppressants | 7 (50%) | 18 (58%) | 0.75 |
AZA/MTX/others, n | 4/1/2 | 13/0/10 | Â |
Serum creatinine at 6 months, mg/dL | 1.00 (0.83–2.09) | 0.86 (0.70–1.02) | 0.053 |
eGFR at 6 months, mL/min/1.73 m2 | 43 (21–74) | 61 (46–72) | 0.3 |
CRP at 6 months, mg/dL | 0.09 (0.006–0.43) | 0.05 (0.01–0.17) | 0.96 |
MPO-ANCA at 6 months, U/mLa | 1.3 (1–2) | 1 (0.4–2.6) | 0.42 |
MPO-ANCA negative conversion at 6 monthsb | 10 (83%) | 14 (61%) | 0.48 |
TIMP-1 at 6 months, ng/mL | 176 (159–216) | 144 (135–168) | 0.004 |
High TIMP-1 at 6 monthsc | 13 (93%) | 13 (42%) | 0.003 |